MDMA

MDMA is a synthetic empathogen-entactogen that increases release and blocks reuptake of serotonin, dopamine, and norepinephrine. Unlike classical psychedelics, MDMA primarily enhances feelings of emotional closeness, empathy, and reduces fear responses without typically causing hallucinations. This unique pharmacological profile makes it particularly effective for trauma processing, as it allows patients to revisit traumatic memories without overwhelming fear or defensive reactions. MAPS (Multidisciplinary Association for Psychedelic Studies) conducted extensive Phase 3 trials showing MDMA-assisted therapy significantly reduced PTSD symptoms, with 67% of participants no longer meeting PTSD diagnostic criteria after treatment. However, the FDA issued a Complete Response Letter in August 2024 to Lykos Therapeutics, citing concerns about study design, functional unblinding (94% of participants correctly identified receiving MDMA vs placebo), and lack of active comparators. The FDA requested an additional Phase 3 study before reconsideration. Despite this setback, MDMA remains one of the most promising psychedelic medicines, with Australia approving limited psychiatric use in 2023 and Utah launching a pilot program in 2024. The therapeutic mechanism appears to involve temporary reduction in amygdala hyperactivity while increasing prefrontal cortex connectivity, allowing for fear memory reconsolidation.